Skip to main content

Table 3 Multivariate analysis of factors associated with overall survival and progression-free survival in LUAD patients

From: High CTHRC1 expression may be closely associated with angiogenesis and indicates poor prognosis in lung adenocarcinoma patients

VariablesOSPFS
Hazard ratio95% CIP-valueHazard ratio95% CIP-value
Gender1.0740.703–1.6430.7401.2040.790–1.8340.389
Age3.2231.917–5.418<0.0012.0971.344–3.2730.001
Smoking0.9340.563–1.5880.8330.8920.548–1.4510.644
Tumor differentiation0.9460.563–1.5880.8331.3180.802–2.1640.276
Clinical stage2.9962.135–4.204<0.0013.2672.302–4.638<0.001
T classification0.8050.673–1.0160.0670.7300.576–0.9250.009
N classification0.9110.665–1.2500.5650.7960.576–1.1000.167
M classification1.4330.628–3.2690.3931.1630.504–2.6860.732
CTHRC1 expression1.0971.029–1.1700.0041.1331.061–1.211<0.001
VEGF expression0.9870.927–1.0510.6801.0330.970–1.1000.313
MVD count1.0150.999–1.0300.0601.0050.990–1.0200.507
  1. CI confidence interval; statistical significance (P < 0.05) is shown in italic
  2. LUAD lung adenocarcinoma, OS overall survival, PFS progression-free survival, CTHRC1 collagen triple helix repeat containing 1, VEGF vascular endothelial growth factor, MVD microvessel density, TNM tumor-node-metastasis, CI confidence interval